Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
AstraZeneca's (AZN) Lupus Drug Saphnelo Gets Europe Nod
by Zacks Equity Research
AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.
Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion
by Zacks Equity Research
Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Horizon Therapeutics (HZNP) Down 6.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Horizon (HZNP) Gets Positive CHMP Opinion for Uplizna in NMOSD
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval to Horizon's (HZNP) Uplizna for treating adult patients with neuromyelitis optica spectrum disorder.
Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.
Horizon Therapeutics (HZNP) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 13.64% and 5.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics (HZNP) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Horizon Therapeutics (HZNP) Might Surprise This Earnings Season
by Zacks Equity Research
Horizon Therapeutics (HZNP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Charles River (CRL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strong gains from the recent Cantel Medical buyout as well as the addition of a new Dental arm are expected to have contributed STERIS' (STE) Q2 performance.
Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Horizon Therapeutics (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If You Invested $1000 in Horizon Therapeutics 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
3 Reasons Why Growth Investors Shouldn't Overlook Horizon Therapeutics (HZNP)
by Zacks Equity Research
Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.
Biogen's (BIIB) Tofersen Reports Mixed Data From ALS Study
by Zacks Equity Research
Biogen's (BIIB) phase III study evaluating tofersen for ALS with SOD1 mutation fails to meet the primary endpoint of the study. However, the study shows signs of reduced disease progression with tofersen.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Anthem (ANTM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) third-quarter results are likely to reflect gains from increased premiums, and strong membership growth across its Medicare and Medicaid businesses, partly offset by rising expenses.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
J&J (JNJ) Seeks Stelara Label Expansion in Juvenile Arthritis
by Zacks Equity Research
J&J (JNJ) files a regulatory application, seeking the label expansion of its inflammatory drug, Stelara, as a potential treatment of juvenile psoriatic arthritis.
Boston Scientific (BSX) Reports Data Backing Eluvia Stent
by Zacks Equity Research
The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.
Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease
by Zacks Equity Research
Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Here's How Much a $1000 Investment in Horizon Therapeutics Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.